Daily News
Daily News

S-adenosylmethionine (SAMe) rescues cognitive deficits in animal research

CDC & FDA Daily

2020 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at CDC & FDA Daily -- Fresh data on Drugs and Therapies - S-Adenosylmethionine Therapy are presented in a new report. According to news reporting originating in Parkville, Australia, by NewsRx journalists, research stated, “Alterations in the methionine cycle and abnormal tau phosphorylation are implicated in many neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. rTg4510 mice express mutant human P301L tau and are a model of tau hyperphosphorylation. The cognitive deficit seen in these animals correlates with a burden of hyperphosphorylated tau and is a model to test therapies aimed at lowering phosphorylated tau.”

The news reporters obtained a quote from the research from the University of Melbourne, “This study aimed to increase protein phosphatase 2A activity through supplementation of S-adenosylmethionine and analyze the effect on spatial memory and tau in treated animals. 6-month-old rTg4510 mice were treated with 100 mg/kg S adenosylmethionine by oral gavage for 3 weeks. Spatial recognition memory was tested in the Y-maze. Alterations to phosphorylated tau and protein phosphatase 2A were explored using immunohistochemistry, western blot, and enzyme-linked immunosorbent assays. Treatment with S-adenosylmethionine increased the Y-maze novel arm exploration time and increased both the expression and activity of protein phosphatase 2A. Furthermore, treatment reduced the number of AT8 positive neurons and reduced the expression of phosphorylated tau (Ser202/Thr205). S-adenosylmethionine contributes to multiple pathways in neuronal homeostasis and neurodegeneration.”

According to the news reporters, the research concluded: “This study shows that supplementation with S-adenosylmethionine stabilizes the heterotrimeric form of PP2A resulting in an increase the enzymatic activity, a reduced level of pathological tau, and improved cognition.”

For more information on this research see: S-Adenosylmethionine Rescues Cognitive Deficits in the rTg4510 Animal Model by Stabilizing Protein Phosphatase 2A and Reducing Phosphorylated Tau. Journal of Alzheimer’s Disease, 2020;():. Journal of Alzheimer’s Disease can be contacted at: IOS Press, Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands.

Our news correspondents report that additional information may be obtained by contacting Xiang M. Liu, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia. Additional authors for this research include Leah C. Beauchamp, Amelia Sedjahtera, Mirjana Bogeski, Laura J. Vella, Ashley I. Bush, Paul A. Adlard and Kevin J. Barnham.

The publisher of the Journal of Alzheimer’s Disease can be contacted at: IOS Press, Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands.

(Our reports deliver fact-based news of research and discoveries from around the world.)